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INTRODUCTION
Ebola Virus Disease (EVD) is part of the group of illnesses 
known as viral haemorrhagic fevers, and was previously 
known as Ebola haemorrhagic fever. Infection with EVD 
is acute, severe and often fatal in humans. Five species of 
the Ebolaviruses have been identified: Zaire, Bundibugyo, 
Sudan, Reston and Tai Forest [1]. The Zaire, Bundibugyo 
and Sudan ebolaviruses were responsible for the largest 
outbreaks in Africa [2]. This paper aims to provide an 
outline of what is known about EVD.
EPIDEMIOLOGY
The EVD occurs in both non-human primates and 
humans, but the largest outbreak so far was in humans. The 
first cases of EVD came in 1976 from two simultaneous 
outbreaks from Zaire (now the Democratic Republic 
of Congo) and southern Sudan (now South Sudan) [2]. 
Both, the Zaire ebolavirus and the Sudan ebolavirus were 
responsible for these outbreaks, which in Zaire, have 
caused 280 deaths out of 318 cases (88% case fatality 
rate) [3]. Much later, cases were reported from eastern 
and western African countries [4].  Between 1976 and 
2015 the Ebolavirus has affected over 31,000 and killed 
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around 13,000 people worldwide [2]. The largest outbreak 
since the discovery of the ebolavirus in 1976 occurred in 
West Africa between 2014 and 2016 [2]. This outbreak 
started in Guinea, then spread across land borders to 
neighboring Sierra Leone and Liberia, and has killed 
over 11,000 people out of more than 28,000 identified 
cases [5]. During these outbreaks, EVD also affected other 
countries such as Italy, Mali, Nigeria, Senegal, Spain, 
the United Kingdom and the United States [5]. Failure to 
contain the outbreak in Guinea due to weak surveillance 
and poor health infrastructure led to the massive spread of 
the disease across the different borders. Overcrowding in 
urban areas, increased movement across the borders and 
poor personal infection prevention practices worsened the 
situation. A recent outbreak was announced in the North 
Kivu and Ituri provinces of the Democratic Republic of 
Congo in August 2018, killing 92 people as of September 
2018 [6].
TRANSMISSION
EVD is zoonotic (i.e. it normally exists in animals but can 
be transmitted to humans), and fruit bats are considered 
to be the main reservoir [7, 8] - see figure 1. The Ebola virus 
Figure 1. The life cycle of ebolavirus (credit: CDC)
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enters the human body when breaks in the mucosa or 
skin come into contact with the blood, secretions, other 
bodily fluids and organs of infected animals like fruit bats, 
monkeys, chimpanzees, gorillas, porcupines and forest 
antelopes. Once in the human body, the virus can be 
transmitted from one human to another through direct 
contact with  bodily fluids or organs of infected persons, 
and also with materials and surfaces soiled with these 
fluids [2]. Contaminated materials and surfaces can be 
anything, such as beddings, clothing, etc. EVD can also 
be transmitted from human-to-human through sexual 
intercourse up to 6 months after developing the disease 
[9]. Ebolavirus transmission can also occur during burial 
ceremonies, when there is direct contact with the dead 
body of an infected person. Healthcare workers often get 
infected when treating Ebola infected persons, especially 
when they do not follow appropriate infection control 
measures. Ebola infected people continue to infect others 
as long as they have the virus in their blood. 
CLINICAL PRESENTATION
The incubation period is 2-21 days, although in most 
cases, symptoms occur within two weeks of infection [2, 10, 
11]. The initial symptoms of EVD include fever, headache, 
fatigue, muscle/body pain and sore throat [2]. This can 
be followed by epigastric and abdominal pain, nausea, 
vomiting, diarrhoea, rash, hiccups, chest pain, symptoms 
of impaired liver and kidney functions, and internal and 
external bleeding such as gum bleeding, blood in stools 
and blood in vomitus. [2, 12]. Laboratory findings include 
raised liver enzymes and reduced white blood cells and 
platelets counts, raised blood urea nitrogen, creatinine 
and lactate levels, reduced plasma sodium, potassium and 
calcium levels, and abnormal coagulation profile [2, 10]. 
DIAGNOSIS
It is very difficult to diagnose EVD based on symptoms 
because in the early stages of the disease it presents like 
other diseases, such as malaria, typhoid and meningitis. 
However, during outbreaks, case definition using specific 
criteria can be used to help in diagnosis (see Table 1). 
Laboratory methods used to detect infection with the 
Ebolavirus include:
1. serologic tests that detects human antibodies 
produced against the Ebolavirus,
2. antigen tests that detect proteins from the 
Ebolavirus,
3. molecular tests that detect viral nucleic acid (RNA) 
sequences, and
4. the traditional gold standard isolation of the 
Ebolavirus by cell culture [2, 13].  
TREATMENT
There is no available specific treatment for the EVD. 
Current treatment is supportive with oral rehydration 
and intravenous fluids including blood transfusion, and 
treatment of specific symptoms. Currently, other potential 
treatment options including drug and immune therapies, 
and blood products are being evaluated [2]. 
PREVENTION AND CONTROL
Control of EVD outbreak involve implementation of 
an intervention package that includes case management, 
surveillance and contact tracing, laboratory diagnosis, safe 
burials, social mobilization and community involvement 
[2]. People should be informed of the following [2, 14]:
• Prevention of transmission from animal-to-
human: avoiding direct contact with sick animals 
(fruit bats, monkeys, chimpanzees, etc.) and 
consumption of their raw meat;
• Prevention of transmission from human-to-
human: avoiding direct/close contact with people 
having Ebola symptoms. When taking care of the 
Ebola sick person, gloves and other appropriate 
personal protective equipment should be worn. 
Hands should regularly be washed after caring for 
the Ebola sick patients in hospital or at home;
• Prevention of sexual transmission: safe sex and 
hygiene should be practiced for 12 months from 
start of Ebola disease symptoms by male survivors 
of EVD and their sexual partners or using a PCR, 
testing can be started at 3 months of onset of Ebola 
symptoms and then monthly until their semen tests 
negative for the Ebolavirus on 2 separate occasions 
at least 1 week apart. During this period, healthcare 
providers should ensure that all EVD survivors and 
their sexual partners receive counselling on safe sex 
practices;
Persons under investigation (PUI)
PUI is any person with both consistent symptoms or 
signs and risk factors as follows:
1. High body temperature or subjective fever or 
symptoms including severe headache, fatigue, 
muscle pain, vomiting, diarrhoea, abdominal pain, 
or unexplained haemorrhage; AND
2. An epidemiological risk factor within the 21 days 
before the start of symptoms.
Confirmed case
Laboratory-confirmed diagnostic evidence of Ebolavirus 
infection. 
Table 1: Case definition for Ebola Virus Disease [5]
South Sudan Medical Journal Vol 11. No 4 November 2018 102
• Measures to contain outbreaks: this includes 
identification of people who have been in contact 
with an EVD patient and monitoring them for 21 
days, practicing safe burial of the dead, separation 
of healthy individuals from the Ebola patients to 
prevent transmission, and practicing good hygiene 
while maintaining clean environment.
Healthcare workers should perform thorough standard 
precautions and protective measures to prevent contact 
with infected blood and body fluids and contaminated 
surfaces or materials. This should include basic hygiene, 
respiratory hygiene, wearing of personal protective 
equipment (face shield/mask, goggle, clean non-sterile 
long-sleeve protective gown, gloves and boots), safe 
injection practices, safe burial practices, and safe handling 
of infected samples for laboratory tests from humans or 
animals [2]. 
A vaccine called rVSV-ZEBOV is currently being used in 
the DRC outbreak, as it is proven to be highly protective 
against the Ebolavirus [15, 16].  WHO recommends that as 
long as there is no licensed candidate vaccine, the rVSV-
ZEBOV vaccine should be used during outbreaks with 
the Zaire Ebolavirus species, but with informed consent 
and good clinical practice [17]. 
CONCLUSION
Infection with the Ebolavirus is rare but deadly and has 
no borders if outbreaks are not contained. However, if 
appropriate measures are thoroughly and promptly taken, 
its transmission can be prevented and controlled, especially 
given the effectiveness of the existing tools, including the 
new vaccine. 
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